A Phase 3 interventional study of Semaglutide 3 mg and Placebo in Obesity, Diabetes and Metabolic Syndrome, sponsored by University College, London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University College, London · Phase 3, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies testing semaglutide in Obesity — 70 open to participants now, 79 under way, 15 of them phase 3. Semaglutide · Obesity.
Among the 145 studies testing semaglutide in Obesity, this one is the 91st largest by enrollment, is one of 19 that started in 2022, is one of 43 in phase 3, and was the 34th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →70 of the 145 studies testing semaglutide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Men only
McMaster University · Sites in Canada
Ages 18–60
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 25 · Phase 3 47 · Phase 4 40
First in 2014; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 100 across the 145 interventional studies. Of the 60 that completed or were terminated, 35 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 145 have an industry lead sponsor. The 10 most frequent:
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
10 studies in Obesity by University College, London: 1 open now, 1 under way, none of them phase 3. Of 6 finished, 1 (17%) have results posted.
Among the 10 studies in Obesity by University College, London, this one is one of 2 that started in 2022, is the only one in phase 3, and was the 7th registered.
University College, London’s Obesity studies by the year they started, since 2018.
22 of the studies testing semaglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT07430059Vivani Medical, IncSafety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | 2026-12 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
| NCT05173714Srinvasan BeddhuSit Less, Interact and Move More (SLIMM) 2 Study | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 145 studies testing semaglutide in Obesity, from their registry updates:
Among University College, London’s 10 in Obesity:
This tab as a report to print or save as PDF → With an account.
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients with poor weight-loss following bariatric surgery. The primary aim of this trial is to determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients with poor weight loss following gastric bypass or sleeve gastrectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
Drug: Semaglutide 3 mg
Placebo administration, once weekly, subcutaneous injection.
Drug: Placebo
Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
Placebo
Percentage Weight Change
Weight change = \[(Weight at Visit 68 minus weight at baseline)/ weight at baseline\]\*100. Positive values represent weight gain and negative values represent weight loss.
Time frame: Baseline and week 68
Categorical Weight Loss
Cumulative percentage of participants who met the criteria for each weight loss threshold (\<10%, ≥10%, ≥15%, ≥20%) at 68 weeks
Time frame: Baseline to 68 weeks
Body Mass Index (BMI)
Change in Body Mass Index from baseline to 68 weeks
Time frame: Baseline to 68 weeks
Body Composition
Change in body composition (measured by Bioelectrical Impedance Analysis) from baseline to 68 weeks
Time frame: Baseline to 68 weeks
Blood Pressure Change
Change in systolic and diastolic Blood Pressure from baseline to 68 weeks. Blood pressure change = Week 68 value minus Baseline value
Time frame: Baseline to 68 weeks
Cardiovascular Outcome - Heart Rate
Change in heart rate from baseline to 68 weeks
Time frame: baseline to 68 weeks
HbA1c
Change in HbA1c from baseline to 68 weeks
Time frame: Baseline to 68 weeks
Lipid Profile
Mean changes in total cholesterol and triglycerides from baseline to 68 weeks
Time frame: Baseline to 68 weeks
High-sensitivity C-reactive Protein (hsCRP)
Mean change in High-sensitivity C-reactive protein (hsCRP) from baseline to 68 weeks
Time frame: Baseline to 68 weeks
Change in IWQOL-Lite (Impact of Weight on Quality of Life)
The 'Impact of Weight on Quality of Life' is a 5 point Likert scale ranging from 1 = "Never true" to 5 = "Always true". It consist of five subscales (physical function, self-esteem, sexual life, public distress and work). Average scores are computed if a minimum of 50% of the items for each scale are answered, and for the total score only if 75% of all items are completed. The average score is multiplied by the total number of items for each scale. The total score is a mean of all available items averaged together. The averaged scores are then transformed and reversed, to be from 0 lowest (worst), to 100 highest (best) quality of life. The change in IQWOL-Lite scores from baseline to 68 weeks was calculated by week 68 score minus baseline score".
Time frame: Baseline to 68 weeks
Change in Systolic Blood Pressure and Diastolic Blood Pressure in Participants With Pre-existing Hypertension
Change in systolic and diastolic BP from baseline to 68 weeks in participants with pre-existing hypertension. Blood pressure change = Week 68 value minus Baseline value
Time frame: Baseline to 68 weeks
HbA1c in Participants With Pre-existing Type 2 Diabetes
Change in HbA1c from baseline to 68 weeks in participants with pre-existing Type 2 Diabetes. HbA1c change = Week 68 value minus Baseline value
Time frame: Baseline to 68 weeks
Change in Circulating HbA1c Levels in Participants With Pre-diabetes
Change in circulating HbA1c levels in participants with pre-diabetes from baseline to 68 weeks
Time frame: Baseline to 68 weeks
Participants were recruited via Bariatric Clinics across 2 London hospitals between 1 November 2022 and 02 November 2023, with follow up of the final patient on 09 April 2025.
| Milestone | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Started | 35 | 35 |
| Completed | 29 | 34 |
| Not completed | 6 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
Weight change = \[(Weight at Visit 68 minus weight at baseline)/ weight at baseline\]\*100. Positive values represent weight gain and negative values represent weight loss.
| percentage change | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Percentage Weight Change | 0.4 ± 7.0 | -18.0 ± 9.2 |
Cumulative percentage of participants who met the criteria for each weight loss threshold (\<10%, ≥10%, ≥15%, ≥20%) at 68 weeks
| percentage of pariticpants | Placebo | Semaglutide 2.4mg |
|---|---|---|
| <10% weight loss | 93.1 | 14.7 |
| ≥10% weight loss | 6.9 | 85.3 |
| ≥15% weight loss | 6.9 | 61.8 |
| ≥20% weight loss | 3.4 | 47.1 |
Change in Body Mass Index from baseline to 68 weeks
| Kg/m^2 | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Body Mass Index (BMI) | 0.03 ± 1.0 | -7.9 ± 1.0 |
Change in body composition (measured by Bioelectrical Impedance Analysis) from baseline to 68 weeks
| kg | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Adjusted mean change in fat mass | 0.9 ± 2.3 | -15.8 ± 2.3 |
| Adjusted mean change in lean soft mass | -0.2 ± 1.2 | -5.5 ± 1.2 |
Change in systolic and diastolic Blood Pressure from baseline to 68 weeks. Blood pressure change = Week 68 value minus Baseline value
| mmHg | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Adjusted mean change in Systolic blood pressure | 2.00 ± 3.1 | -3.9 ± 3.3 |
| Adjusted mean change in Diastolic blood pressure | 5.85 ± 2.3 | 1.64 ± 2.5 |
Change in heart rate from baseline to 68 weeks
| beats per minute (bmp) | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Cardiovascular Outcome - Heart Rate | -6.6 ± 2.4 | -4.9 ± 2.7 |
Change in HbA1c from baseline to 68 weeks
| mmol/mol | Placebo | Semaglutide 2.4mg |
|---|---|---|
| HbA1c | 1.7 ± 0.8 | -3.6 ± 0.8 |
Mean changes in total cholesterol and triglycerides from baseline to 68 weeks
| Mmol/l | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Total cholesterol | 0.2 ± 0.2 | -0.3 ± 0.2 |
| Triglycerides | 0.2 ± 0.2 | -0.3 ± 0.2 |
Mean change in High-sensitivity C-reactive protein (hsCRP) from baseline to 68 weeks
| Mg/l | Placebo | Semaglutide 2.4mg |
|---|---|---|
| High-sensitivity C-reactive Protein (hsCRP) | 1.4 ± 1.5 | 0.4 ± 1.6 |
The 'Impact of Weight on Quality of Life' is a 5 point Likert scale ranging from 1 = "Never true" to 5 = "Always true". It consist of five subscales (physical function, self-esteem, sexual life, public distress and work). Average scores are computed if a minimum of 50% of the items for each scale are answered, and for the total score only if 75% of all items are completed. The average score is multiplied by the total number of items for each scale. The total score is a mean of all available items averaged together. The averaged scores are then transformed and reversed, to be from 0 lowest (worst), to 100 highest (best) quality of life. The change in IQWOL-Lite scores from baseline to 68 weeks was calculated by week 68 score minus baseline score".
| scores on a scale | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Change in IWQOL-Lite (Impact of Weight on Quality of Life) | 9.3 ± 3.9 | 23.7 ± 4.1 |
Change in systolic and diastolic BP from baseline to 68 weeks in participants with pre-existing hypertension. Blood pressure change = Week 68 value minus Baseline value
| mmHg | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Systolic Blood Pressure | 9.4 ± 3.8 | -2.2 ± 3.9 |
| Diastolic Blood Pressure | 7.9 ± 2.9 | 6.3 ± 3.2 |
Change in HbA1c from baseline to 68 weeks in participants with pre-existing Type 2 Diabetes. HbA1c change = Week 68 value minus Baseline value
| mmol/mol | Placebo | Semaglutide 2.4mg |
|---|---|---|
| HbA1c in Participants With Pre-existing Type 2 Diabetes | 4 ± 1.5 | -3.4 ± 1.8 |
Change in circulating HbA1c levels in participants with pre-diabetes from baseline to 68 weeks
| Mmol/mol | Placebo | Semaglutide 2.4mg |
|---|---|---|
| Change in Circulating HbA1c Levels in Participants With Pre-diabetes | 0.2 ± 1.6 | -8.0 ± 2.3 |
Collected over 74 weeks (68 weeks of treatment and 6 week wash out period). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/35 (0%) | 8/35 (22.9%) | 33/35 (94.3%) |
| Semaglutide 2.4mg | 0/35 (0%) | 3/35 (8.6%) | 34/35 (97.1%) |
| Event | Placebo | Semaglutide 2.4mg |
|---|---|---|
| PancreatitisHepatobiliary disorders | 2/35 | 0/35 |
| Gastro-oesophageal reflux diseaseGastrointestinal disorders | 1/35 | 0/35 |
| Fractured patellaMusculoskeletal and connective tissue disorders | 1/35 | 0/35 |
| Rupture of right quadriceps tendonMusculoskeletal and connective tissue disorders | 1/35 | 0/35 |
| GallstonesHepatobiliary disorders | 1/35 | 0/35 |
| Spontaneous bruisingBlood and lymphatic system disorders | 0/35 | 1/35 |
| Acute Coronary SyndromeCardiac disorders | 1/35 | 0/35 |
| Abdominal wall abscessGastrointestinal disorders | 0/35 | 1/35 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/35 | 0/35 |
| BradycardiaCardiac disorders | 1/35 | 0/35 |
| Event | Placebo | Semaglutide 2.4mg |
|---|---|---|
| otherGeneral disorders | 29/35 | 30/35 |
| NauseaGastrointestinal disorders | 8/35 | 24/35 |
| DiarrhoeaGastrointestinal disorders | 14/35 | 21/35 |
| Decreased appetiteGastrointestinal disorders | 4/35 | 15/35 |
| Upper respiratory tractInfections and infestations | 10/35 | 14/35 |
| HeadacheNervous system disorders | 10/35 | 14/35 |
| ConstipationGastrointestinal disorders | 8/35 | 13/35 |
| DizzinessGastrointestinal disorders | 5/35 | 12/35 |
| FatigueGeneral disorders | 10/35 | 12/35 |
| VomitingGastrointestinal disorders | 6/35 | 10/35 |
| Age, Categorical(Participants) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 35 | 35 | 70 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Mean | 47.7 ± 10.3 | 46.9 ± 10.4 | 47.3 ± 10.3 |
| Sex: Female, Male(Participants) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Female | 28 | 30 | 58 |
| Male | 7 | 5 | 12 |
| Race (NIH/OMB)(Participants) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 6 | 16 |
| White | 21 | 26 | 47 |
| More than one race | 4 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Bodyweight (kg)(units on scale) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Mean | 111.4 ± 19.3 | 118.6 ± 23.3 | 115 ± 12.6 |
| Body Mass Index(kg/m^2) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Mean | 40.2 ± 6 | 42.8 ± 6.8 | 41.5 ± 6.5 |
| Procedure Type(Participants) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Sleeve gastrectomy | 28 | 27 | 55 |
| Gastric bypass | 7 | 8 | 15 |
| Time Since Surgery(months) | Placebo | Semaglutide 2.4mg | Total |
|---|---|---|---|
| Mean | 79.1 ± 34.2 | 88.6 ± 50.5 | 83.9 ± 43.1 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2022 to primary completion in Apr 2025, 29 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion.
Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's 29 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Mar 2025 → Apr 2025 and completion Sep 2025 → Apr 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide